{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:19:44Z","timestamp":1775218784567,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T00:00:00Z","timestamp":1453852800000},"content-version":"vor","delay-in-days":605,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Keelung Chang Gung Memorial Hospital, Taiwan"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jmii.2013.09.006","type":"journal-article","created":{"date-parts":[[2013,11,16]],"date-time":"2013-11-16T02:30:14Z","timestamp":1384569014000},"page":"245-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia"],"prefix":"10.1016","volume":"47","author":[{"given":"Sai-Cheong","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiang-Ju","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Huan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Jiun","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai-Chu","family":"See","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2013.09.006_bib1","doi-asserted-by":"crossref","first-page":"86S","DOI":"10.1016\/0002-9343(91)90349-3","article-title":"Secular trends in nosocomial primary bloodstream infections in the United States, 1980\u20131989","volume":"91","author":"Banerjee","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.jmii.2013.09.006_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/01.CCM.0000202208.37364.7D","article-title":"A bedside scoring system (\u201cCandida score\u201d) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization","volume":"34","author":"Le\u00f3n","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jmii.2013.09.006_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1086\/375080","article-title":"Caspofungin","volume":"36","author":"Deresinski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.09.006_bib4","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkg117","article-title":"Caspofungin: the first representative of a new antifungal class","volume":"51","author":"Letscher-Bru","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2013.09.006_bib5","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1128\/JCM.42.8.3475-3482.2004","article-title":"Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species","volume":"42","author":"Odds","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2013.09.006_bib6","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.41.11.2326","article-title":"In\u00a0vitro preclinical evaluation studies with the echinocandin antifungal MK-0991(L-743,872)","volume":"41","author":"Bartizal","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2013.09.006_bib7","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/AAC.41.11.2333","article-title":"Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis","volume":"41","author":"Abruzzo","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2013.09.006_bib8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/JCM.44.3.760-763.2006","article-title":"In\u00a0vitro Susceptibilities of Candida spp. to caspofungin: for years of global surveillance","volume":"44","author":"Pfaller","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2013.09.006_bib9","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2013.09.006_bib10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.09.006_bib11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2013.09.006_bib12","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.09.006_bib13","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2013.09.006_bib14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.clinthera.2008.04.020","article-title":"Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"Schonfeld","year":"2008","journal-title":"Clin Therapeutics"},{"key":"10.1016\/j.jmii.2013.09.006_bib15","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/AAC.48.4.1382-1383.2004","article-title":"Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive candida esophagitis","volume":"48","author":"Hernandez","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2013.09.006_bib16","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/jac\/dkh179","article-title":"Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study","volume":"53","author":"Kartsonis","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2013.09.006_bib17","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2013.09.006_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.09.006_bib19","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1128\/AAC.44.10.2715-2718.2000","article-title":"Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole","volume":"44","author":"Lee","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2013.09.006_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0149-2918(02)85039-1","article-title":"Caspofungin: an echinocandin antifungal agent","volume":"3","author":"Stone","year":"2002","journal-title":"Clin Therapeutics"},{"key":"10.1016\/j.jmii.2013.09.006_bib21","first-page":"354","article-title":"Micafungin, a new echinocandin antifungal","volume":"38","author":"Young","year":"2003","journal-title":"Formulary"},{"key":"10.1016\/j.jmii.2013.09.006_bib22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1378\/chest.100.6.1619","article-title":"The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults","volume":"100","author":"Knaus","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.jmii.2013.09.006_bib23","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement","author":"Rex","year":"2008"},{"key":"10.1016\/j.jmii.2013.09.006_bib24","series-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"Galgiani","year":"2008"},{"key":"10.1016\/j.jmii.2013.09.006_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.09.006_bib26","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrel","year":"2005","journal-title":"Antimicrob Agent Chemother"},{"key":"10.1016\/j.jmii.2013.09.006_bib27","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/JCM.00131-07","article-title":"Biofilm production by candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia","volume":"45","author":"Tumbarello","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2013.09.006_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.md.0000091182.93122.8e","article-title":"Candidemia in a tertiary care cancer center in\u00a0vitro susceptibility and its association with outcome of initial antifungal therapy","volume":"82","author":"Antoniadou","year":"2003","journal-title":"Medicine"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118213001734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118213001734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:18:45Z","timestamp":1761657525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118213001734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1684118213001734"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2013.09.006","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2013.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}